Ioversol
This non-ionic, low-osmolality iodinated contrast agent is used for coronary angiography, CT scans, urography, and other diagnostic imaging. Its favorable safety profile makes it suitable for a wide range of patients including those with mild to moderate renal impairment. Standard precautions for iodinated contrast including allergy screening and post-procedure hydration apply.
分子量
807.1000 g/mol
LogP
-3.00
TPSA
200.00 Ų
リピンスキーの五則
不適合
治療領域
作用機序
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
2D構造
Cite this structure
Embed this structure
SMILES
O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I
InChI
InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)
Molecular Formula
C18H24I3N3O9
HBD / HBA
8 / 9
回転可能結合数
12
重原子数
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
This non-ionic, low-osmolality iodinated contrast agent is used for coronary angiography, CT scans, urography, and other diagnostic imaging. Its favorable safety profile makes it suitable for a wide range of patients including those with mild to moderate renal impairment. Standard precautions for iodinated contrast including allergy screening and post-procedure hydration apply.
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Yes, Ioversol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200614. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3741. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ioversol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ioversol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ioversol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ioversol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ioversol"></drugfyi-drug>